Conjunctive analysis of biological marker expression for predicting cardiac mortality

Abstract

A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.

Description

[0001]This is a reissue of U.S. Pat. No. 6,461,828, which issued from application Ser. No. 09 / 946,171, filed Sep. 4, 2001.FIELD OF THE INVENTION[0002]This invention relates to the concept of conjunctive utilization of biological markers expressed in response to abnormal pressure, volume change and stress to a particular organ (e.g. N-terminal ANP (pro-ANP) in heart tissue) along with the expression of biological markers that are indicative of tissue damage (e.g. cardiac Troponin I (cTnI), or fibrosis markers for heart tissue) as a diagnostic tool to accurately and rapidly diagnose the condition of the ailing organ. Although this concept is applicable to numerous organ and organ systems, this application will particularly illustrate the concept of conjunctive marker utilization with respect to the heart, specifically with respect to congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTnI) and natriuretic peptides, e.g. b...

AI Technical Summary

Benefits of technology

[0019]The instant invention provides the scientific basis for the development of an immunological test that has the potential to 1) replace expensive and time-consuming imaging techniques so that the appropriate therapeutic intervention may be afforded to the patient soon after arrival into the emergency room, and 2) provide a simplified means for diagnosing, distinguishing and quantifying chronic heart failure and the treatment thereof.

[0025]It is a further objective of the instant invention to provide a test capable of ruling out high risk patients with congestive heart failure, and thereby permitting the most efficient use of medical resources.

[0026]It is yet another objective of the instant invention to describe a test which exhibits improved diagnostic accuracy over clinical evaluation.

[0028]It is yet an additional objective of the instant invention to provide a test which confirms cardiac etiology of symptoms, reduces the need for cardiac imaging, yields data for determining long term management and monitoring, and serves as a predictor of mortality.

Problems solved by technology

However, neither these molecules nor any other natriuretic peptide, e.g. pro-ANP, have been used in conjunction as a diagnostic tool to accurately and rapidly diagnose the condition of the ailing heart.